Terumo targets bioresorbable heart stent market with ART deal
This article was originally published in Clinica
Japanese cardiovascular device maker Terumo has struck a deal with French stent specialist Arterial Remodeling Technologies to invest in the development of a drug-eluting bioresorbable heart stent. The agreement also gives Terumo the exclusive option to buy out ART at any time before initiating clinical trials of the stent.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.